Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
Rheumatol Adv Pract. 2020 Oct 21;4(2):rkaa061.
doi: 10.1093/rap/rkaa061.
eCollection 2020.